Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Opaganib - RedHill Biopharma

Drug Profile

Opaganib - RedHill Biopharma

Alternative Names: ABC 294640; YELIVA

Latest Information Update: 24 Sep 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Apogee Biotechnology Corporation
  • Developer Apogee Biotechnology Corporation; Medical University of South Carolina; RedHill Biopharma
  • Class Adamantanes; Amides; Anti-inflammatories; Antineoplastics; Antirheumatics; Antivirals; Chlorobenzenes; Pyridines; Small molecules
  • Mechanism of Action Sphingosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cholangiocarcinoma
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer; Inflammation

Highest Development Phases

  • Phase II/III COVID 2019 infections
  • Phase II Cholangiocarcinoma; Prostate cancer
  • Phase I/II Multiple myeloma
  • Clinical Phase Unknown Cancer
  • Suspended Liver cancer
  • No development reported Inflammatory bowel diseases; Osteoarthritis; Radiation injuries; Rheumatoid arthritis; Solid tumours

Most Recent Events

  • 22 Sep 2020 Phase-II/III clinical trials in COVID-2019 infections (Adjunctive treatment) in Brazil (PO) (NCT04467840)
  • 22 Sep 2020 Brazilian Health Regulatory Agency (ANVISA) approves CTA application for phase II/III trial in COVID-2019 infections
  • 27 Aug 2020 Phase-II/III clinical trials in COVID-2019 infections (Adjunctive treatment) in Italy (PO) (NCT04467840)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top